Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-
Shares in 2seventy bio were on the slide this morning after the US biotech said Seattle Children’s Therapeutics had paused a clinical trial of its T-cell therapy for acute
The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog
Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to